RayzeBio ^Delisted

RayzeBio is a pharmaceuticals company that focuses on developing targeted radiopharmaceutical drugs for cancer. Their main goal is to improve outcomes for cancer patients by harnessing the power of targeted radioisotopes. They have a diverse portfolio of radiopharmaceutical drug candidates, ranging from discovery to late-stage clinical programs. RayzeBio aims to deliver radioisotopes that emit alpha particles, such as Actinium-225, directly to solid tumors, including metastatic ones. They are considered the emerging leader in radiopharmaceuticals and are dedicated to advancing their pipeline programs to bring innovative treatments to cancer patients.